No Data
No Data
Sumitomo Riko, Shionogi, etc. (additional) rating.
Upgrade-Power Code | Stock Name | Securities Company | Previous | After changing | ------ | --------------- | ------------- | -------------- | -------------- | <2212> | Yamazaki Bread | GS | "Hold" | "Buy" | <4293> | Septeni HD | MSMUFG | "UnderW" | "Iko"
Ube, Kobe Steel, etc. (additional) Rating.
Upgrade - bullish code | Stock name | Securities company | Conventional | Revised | ------ | --------------- | ---------- | --------- | --------- | <9433> | KDDI | Mizuho | "Hold" | "Buy" | Downgrade - bearish code | Stock name | Securities company | Conventional | Revised | ------ | --------------- | ---------- |
The Nikkei average started 95 yen higher, with KOKUSAI, Mercari, and others rising.
[Nikkei Average Stock Price and TOPIX (Table)] Nikkei Average; 41009.36; + 95.71 TOPIX; 2900.18; + 1.71 [Opening Summary] On the 5th, the Nikkei Average opened with a 6th consecutive increase of 95.71 yen to 41009.36 yen. On the previous day, the US market on the 4th was closed for Independence Day. In Europe, the UK's FTSE TM100 rose by 0.86%, Germany's DAX rose by 0.41%, and France's CAC40 rose by 0.83%. Today's Tokyo stock market started with buying. Yesterday's US stock market.
Speee, Astellas Pharma, etc. (Part 2)
<4499> Speee Inc. Rakuten Securities, Inc. shareholding ratio: 5.08% → 0.51%. Reporting obligation date: June 28, 2024.<4503> Astellas Pharma Inc. BlackRock Japan Co., Ltd. shareholding ratio: 8.52% → 7.50%. Reporting obligation date: June 28, 2024.<4674> Cresco Ltd. Iwasaki Corporation shareholding ratio: 20.36% → 20.36%.
China's National Medical Products Administration approved the new indication of Enzalutamide (XTANDI) for the treatment of metastatic hormone-sensitive prostate cancer.
This is the third indication for advanced prostate cancer treatment approved by Enzalutamide in China. Approval is based on positive results from the global and China ARCHES phase III studies. Compared to placebo combined with androgen deprivation therapy (ADT), Enzalutamide combined with ADT significantly delayed progression time of prostate specific antigen (PSA). Tokyo, July 2, 2024 /PRNewswire/ - Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced today that the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an indication extension for XTANDI® (Enzalutamide) capsules to treat adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in China.
Astellas Pharma: Extraordinary Report
No Data